Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (JAZZ)
NASDAQ:JAZZ
Jazz Pharmaceuticals (JAZZ) Stock Price & Analysis
1,422 Followers
JAZZ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$99.06 - $146.70
Previous Close$109.01
Volume385.88K
Average Volume (3M)761.66K
Market Cap
$6.87B
Enterprise Value$11.14B
Total Cash (Recent Filing)$1.51B
Total Debt (Recent Filing)$5.77B
Price to Earnings (P/E)23.7
Beta0.52
Next Earnings
Jul 31, 2024EPS Estimate
$4.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.60
Shares Outstanding63,039,618
10 Day Avg. Volume946,821
30 Day Avg. Volume761,657
Standard Deviation0.09
R-Squared0.14
Alpha-0.00673
Financial Highlights & Ratios
Price to Book (P/B)-1.98
Price to Sales (P/S)1.77
Price to Cash Flow (P/CF)10.20
P/FCF Ratio8.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.91
Enterprise Value/Gross Profit3.28
Enterprise Value/Ebitda15.58
Forecast
1Y Price Target
$177.83Price Target Upside63.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
Jazz Pharmaceuticals News
PremiumStock Analysis & Ideas
‘Load Up,’ Says Goldman Sachs About These 2 Strong Buy Stocks
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe zani triplet study arm could validate a broader market opportunity of more than $1bn.
Revenue GrowthJazz Pharmaceuticals is on track to achieve its Vision 2025 goal of $5bn topline revenue.
Stock ValuationJAZZ is trading at a higher relative discount to the S&P than its 5-year average, making it attractive at current levels.
Bears Say
Clinical TrialsThe trial did not achieve statistical significance at 30mg versus placebo in the primary endpoint or key secondary endpoint.
EarningsJazz reported 1Q24 non-GAAP EPS of $2.68, which was lower than non-GAAP consensus of $4.18.
Financial PerformanceJazz kicked 2024 results off with sloppy 1Q results—one of its largest top and bottom line misses in memory.
---
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
JAZZ FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was $99.06 and its highest was $146.70 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Jul 31, 2024 which is in 9 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on May 01, 2024. The company reported $2.68 earnings per share for the quarter, missing the consensus estimate of $4.179 by -$1.499.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is $4.8.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 63,062,355 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of $2.68 in its last earnings report, missing expectations of $4.179. Following the earnings report the stock price went down -0.925%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 173M.
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$177.83 (63.13% Upside)
$177.83 (63.13% Upside)
Blogger Sentiment
Bullish
JAZZ Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 204.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $548.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.90%
12-Months-Change
Fundamentals
Return on Equity
9.41%
Trailing 12-Months
Asset Growth
2.53%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
JAZZ Company Deck
---
JAZZ Earnings Call
Q1 2024
0:00 / 0:00
---
JAZZ Stock 12 Month Forecast
Average Price Target
$177.83
▲(63.13% Upside)
Technical Analysis
Best Analysts Covering JAZZ
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+2.83%
reiterated a buy rating 2 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +2.83% per trade.
---